Myomo, Inc.: In Motion To Accelerating Revenue Growth

Kameleon007 Background Myomo (NYSE:MYO) is an under-followed, under-owned, under-appreciated and under-valued company with extraordinary potential. I explained in my last article, in December 2003, that the lucrative reimbursement rate Medicare proposed last year would not be reduced. Indeed, on February 29th Medicare posted their decision to finalize MyoPro reimbursement at $65,872. This created a brand-new industry and will change the lives of patients suffering from arm paralysis. Since MYO is not yet on the radar screen of institutional investors, the valuation of the company has not begun to reflect the value of their business prospects. Given that all reimbursement risk…